Comparison of Two Prominent Dividend Kings: AbbVie and Johnson & Johnson
The case for AbbVie
AbbVie, despite revenue declines, shows resilience with a lineup of new medicines like Skyrizi and Rinvoq. These drugs are expected to surpass Humira's sales, showcasing growth potential for the company. With ongoing programs and new product approvals, AbbVie remains a strong contender in the pharmaceutical industry.
Key Points:
- Revenue decline countered by new drug sales
- Over 50 years of consecutive dividend growth
- AbbVie offers higher yield and sustainable payout ratio
The case for Johnson & Johnson
Johnson & Johnson's diverse portfolio and innovative pipeline position it as a leader in healthcare. The company's focus on developing cutting-edge medicines and expanding its medtech division enhances growth opportunities. Despite regulatory challenges, Johnson & Johnson's solid operations and dividend track record make it a reliable choice for investors.
Key Points:
- Acquisition of Abiomed strengthens medical device segment
- 61 years of consecutive dividend increases
- Stable revenue growth and sustainable payout
In conclusion, while both companies offer solid dividend prospects, AbbVie emerges as the better choice for investors seeking higher yield and potential growth.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.